Key Drivers
- High gross margin
- Negative net income
- Elevated intangibles
AIAI Summary
Elanco has shifted from an acquisition/turnaround credit story to an innovation-led growth thesis where 2026 margin expansion and deleveraging materially depend on successful commercialization of the “Big 6” and realization of Elanco Ascend cost savings—if innovation revenue hits ~$1.15B and adjusted EBITDA reaches $955–985M, leverage should move toward ~3.1–3.3x and validate upside. Monitor quarterly adoption metrics (Credelio Quattro, Befrena, Zenrelia), adjusted EBITDA/FCF trends, and any intangible-impairment signals—misses would rapidly re-elevate financing and valuation risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Negative net income
- •Elevated intangibles
Elanco produces strong gross margins and cash generation but faces recurring net losses, heavy intangibles and notable leverage that elevate impairment and profitability risk.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •RSI bearish (≈38)
- •Holds ~$22.7 support
ELAN shows a modestly bearish short-term tilt: price closed below its last-month SMA with RSI around 38, holding near $22.68 support but facing resistance in the $24.64–$26.8 band. #defined-risk
Series of lower closes since the late-February peak indicates short-term downward bias
Sentiment & News
Key News Insights:
- •Innovation beat
- •Raised guidance
- •Mixed investor response
Elanco posted solid Q4 and FY25 revenue growth, beat its 2025 innovation target and raised 2026 innovation guidance while providing modest 2026 revenue/EBITDA guidance amid mixed investor signals.
Strong innovation momentum and upgraded targets support valuation upside, but large institutional selling and a one-day stock spike introduce near-term sentiment volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings